| Active, not recruiting | 2 | 256 | Europe, Canada, US, RoW | Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvyâ„¢, GS-0132, M6223, NKTR-255 | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics | Locally Advanced or Metastatic Urothelial Carcinoma | 01/25 | 01/25 | | |